TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05843006

Intervention type: DIAGNOSTIC_TEST
Intervention: Examination and analysis of sweat and blood samples at baseline
Description: Sweat samples will be collected using the CE certified Macroduct Sweat Collector and inflammatory parameters measured. Venous blood will be drawn and inflammatory parameters, Troponin-I and nt-proBNP measured. Blood pressure, heart rate, risk scores and health information will collected.
Study: NCT05570591

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2RT subthreshold nanosecond laser - active
Description: The 2RT™ Q-switched YAG laser (532nm) delivering 3 nanosecond pulses; 400 um spot size, is a pulsed subthreshold nanosecond (SNL) laser, which uses low energy levels to produce limited effects that selectively target melanosomes within the pigmented retinal pigment epithelial (RPE) cells.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: 2RT subthreshold nanosecond laser - sham
Description: Application of sham laser (i.e. flashing lights which replicate the look of active laser to the participant) from the 2RT subthreshold nanosecond laser device.
Study: NCT06254742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HHPG-19K Injection
Description: first cycle: Auto-HHPG-19K Injection or HHPG-19K Injection second cycle: HHPG-19K Injection or Auto-HHPG-19K Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HHPG-19K Injection
Description: first cycle: Auto-HHPG-19K Injection or HHPG-19K Injection second cycle: HHPG-19K Injection or Auto-HHPG-19K Injection
Study: NCT06405711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: frame lens
Description: A randomized block group design was used to randomly assign the included study subjects. The appropriate randomization number and random allocation scheme will be given after enrollment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: frame lens
Description: A randomized block group design was used to randomly assign the included study subjects. The appropriate randomization number and random allocation scheme will be given after enrollment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: frame lens
Description: A randomized block group design was used to randomly assign the included study subjects. The appropriate randomization number and random allocation scheme will be given after enrollment.
Study: NCT05680571

Intervention type: DEVICE
Intervention: BulbiCam
Description: BulbiCam is an non-invasive, multi-test device which combined eye tracking; pupil metric; video graphic dual device including the f10 tests under development and ready for validation

Intervention type: DEVICE
Intervention: BulbiCam
Description: BulbiCam is an non-invasive, multi-test device which combined eye tracking; pupil metric; video graphic dual device including the f10 tests under development and ready for validation
Study: NCT05567575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy,
Description: TechCare is based on the intelligent real time therapy (iRTT) conceptual model proposed by Kelly et al. iRTT relates to the use of mobile technologies to deliver interventions such as CBT, extending beyond assessment of symptoms. The intervention is based on the treatment manual developed by David G. Kingdon and Douglas Turkington. The intervention is informed by evidence based cognitive models of psychosis, where the participant is able to choose from a list of pre-selected digital self-help strategies that are personalised to each participant. For example, the App may incorporate the participant's favourite music in the form of multimedia or YouTube links, which are prompted during symptom elevation. Other examples may include psychoeducation, goal setting, problem-solving, etc., based on common self-help strategies in CBT for Psychosis (CBTp).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy,
Description: TechCare is based on the intelligent real time therapy (iRTT) conceptual model proposed by Kelly et al. iRTT relates to the use of mobile technologies to deliver interventions such as CBT, extending beyond assessment of symptoms. The intervention is based on the treatment manual developed by David G. Kingdon and Douglas Turkington. The intervention is informed by evidence based cognitive models of psychosis, where the participant is able to choose from a list of pre-selected digital self-help strategies that are personalised to each participant. For example, the App may incorporate the participant's favourite music in the form of multimedia or YouTube links, which are prompted during symptom elevation. Other examples may include psychoeducation, goal setting, problem-solving, etc., based on common self-help strategies in CBT for Psychosis (CBTp).
Study: NCT04861675

Intervention type: PROCEDURE
Intervention: Full mouth rehabilitation under general anaesethia
Description: Assessment of change in oral health related quality of life , body growth status and oral hygiene status for children with special health care needs after full mouth rehabilitation under general anesethia,
Study: NCT05528315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT04972474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone app in-app components
Description: Insightful notification text, data visualisation, research team contact details.
Study: NCT06159387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis Extract Oil SR Capsule
Description: After randomization, in a double blind model, subjects receive cannabis extract or placebo conditioned in identical vials with the same volume of substance.~Everyone will undergo psychotherapy in the CBT (cognitive behavioral therapy) model

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabis Extract Oil SR Capsule
Description: After randomization, in a double blind model, subjects receive cannabis extract or placebo conditioned in identical vials with the same volume of substance.~Everyone will undergo psychotherapy in the CBT (cognitive behavioral therapy) model
Study: NCT05485584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rSIFN-co Nasal Spray
Description: 8 million IU (16 μg)/day; Once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rSIFN-co Nasal Spray
Description: 16 million IU (32 μg)/day; Twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Spray
Description: Once daily
Study: NCT05442957

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRIGHT
Description: BRIGHT is a manualized theory-based tele-CBT intervention consisting of 6 weekly 60-minute sessions. BRIGHT is delivered one-on-one by a licensed clinical psychologist at each site via standard video tele-CBT platform. BRIGHT session topics include (1) psychoeducation about the cognitive model of body image, (2) self-monitoring about thoughts, feelings, and body image behaviors, (3) cognitive restructuring to identify and challenge unhelpful automatic HNC body image thoughts, (4) positive body image coping strategies, (5) social support and identifying personal value, and (6) thinking ahead and planning for setbacks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: AC is a manualized video-tele-supportive care intervention that addresses non-body image aspects of HNC survivorship. Identical to BRIGHT, AC consists of 6 weekly 60-minute sessions delivered by a trained empathic interventionist via standard video-telemedicine platform. AC session topics include (1) Introduction to HNC survivorship, (2) Post-Treatment Side Effects (3) Psychosocial Aspects of HNC, (4) Health Promotion and Nutritional Challenges, (5) Financial Distress and Return to Work, and (6) Cancer Recurrence. AC controls for professional attention (i.e., ensuring that findings are not driven by simply interacting with an empathic interventionist), common factors, dose, and delivery method while not providing the active, behavior change mechanism in BRIGHT.
Study: NCT06507189

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined endurance and resistance training
Description: ET will consist of 3x/wk training (MWF) with MF being steady state cycling, treadmill, or elliptical at 70-75% HRR for 30 min and the W session being a 20 min high intensity interval session on a cycle ergometer (1 min on/off; 10 cycles) targeting 85-90% HRR. The treadmill and elliptical on M or F will be provided for variety but the mainstay will be cycle ergometry. On MF participants will complete 3 sets x 8-12 repetitions for leg press, knee extension, hamstring curl, chest press, seated row, overhead press, lat pulldown, triceps push-down, and biceps curl in superset fashion \[i.e., alternate between opposing muscle groups without rest (chest press followed by seated row)\] with a 60 s rest between supersets. Sets will be performed with load progression to ensure volitional fatigue in the 8-12 rep range. Core exercises (trunk flexion and extension) will also be included using bodyweight only for 3 sets.
Study: NCT05485584

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Spray
Description: Twice daily
Study: NCT05298189

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MindBreaks - Audio-visual
Description: A MindBreaks room is designed to deliver short, effective, and restorative breaks to help increase energy, reduce stress, enhance mood, improve focus, and boost performance. For this intervention, the MindBreaks room will contain visual and auditory stimuli.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MindBreaks - Auditory-only
Description: A MindBreaks room is designed to deliver short, effective, and restorative breaks to help increase energy, reduce stress, enhance mood, improve focus, and boost performance. For this intervention, the MindBreaks room will contain only auditory stimuli.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MindBreaks - Visual-only
Description: A MindBreaks room is designed to deliver short, effective, and restorative breaks to help increase energy, reduce stress, enhance mood, improve focus, and boost performance. For this intervention, the MindBreaks room will contain only visual stimuli.
Study: NCT05803200

Intervention type: DRUG
Intervention: No intervention
Description: No intervention was given as this is an observational study.
Study: NCT05071079

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: An inoculum of malaria parasitised red blood cells with whole dose blood-stage inoculum
Description: An inoculum of malaria parasitised red blood cells reconstituted in 0.9% normal saline, to a total volume of 5 mL; challenge with whole dose blood-stage inoculum (neat)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: An inoculum of malaria parasitised red blood cells with 1:5 dilution blood-stage inoculum
Description: An inoculum of malaria parasitised red blood cells reconstituted in 0.9% normal saline, to a total volume of 5 mL; challenge with 1:5 dilution blood-stage inoculum

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: An inoculum of malaria parasitised red blood cells with 1:10 dilution blood-stage inoculum
Description: An inoculum of malaria parasitised red blood cells reconstituted in 0.9% normal saline, to a total volume of 5 mL; challenge with 1:10 dilution blood-stage inoculum

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: An inoculum of malaria parasitised red blood cells with 1:20 dilution blood-stage inoculum
Description: An inoculum of malaria parasitised red blood cells reconstituted in 0.9% normal saline, to a total volume of 5 mL; challenge with 1:20 dilution blood-stage inoculum
Study: NCT05122884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milrinone
Description: Prepare milrinone 20 mg with NSS 100 ml then starts dose 0.5 mg/kg/min for up to 12 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Milrinone
Description: Prepare milrinone 20 mg with NSS 100 ml then starts dose 0.5 mg/kg/min for up to 12 hours.
Study: NCT05520346

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic Device for Toilet
Description: Device will be installed on toilet of patients will in hospital to measure all waste output.
Study: NCT06345521

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06201247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JD123 injection
Description: JD123 injection is an universal Off-the-shelf CD123-targeted chimeric antigen receptor modified natural killer cells (CAR-NK) therapy derived from a healthy donor.
Study: NCT04930809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VER-01
Description: standardised cannabis extract (containing 21 mg THC per gram drug product)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VER-01
Description: standardised cannabis extract (containing 21 mg THC per gram drug product)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VER-01
Description: standardised cannabis extract (containing 21 mg THC per gram drug product)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VER-01
Description: standardised cannabis extract (containing 21 mg THC per gram drug product)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VER-01
Description: standardised cannabis extract (containing 21 mg THC per gram drug product)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VER-01
Description: standardised cannabis extract (containing 21 mg THC per gram drug product)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VER-01
Description: standardised cannabis extract (containing 21 mg THC per gram drug product)
Study: NCT06004648

Intervention type: PROCEDURE
Intervention: Upper extremity surgery
Description: Comparison of 2 different peripheral nerve blocks

Intervention type: PROCEDURE
Intervention: Upper extremity surgery
Description: Comparison of 2 different peripheral nerve blocks
Study: NCT05201027

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: trifocal intraocular lens
Description: cataract extraction and implantation of a posterior chamber trifocal intraocular lens
Study: NCT05824286

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HbA1c prediction
Description: HbA1c prediction model was developed based on fasting capillary blood glucose and postprandial capillary blood glucose from self-monitoring blood glucose. Since HbA1c was measured once every 3 month, self-monitoring blood glucose records were transferred to predicted HbA1c by prediction model every month.
Study: NCT05147467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG2575
Description: APG-2575 orally once daily at 600mg dose levels, every 28 days as a cycle.
Study: NCT05310643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Induction therapy with nivolumab 240 mg; 4 infusions, every 3 weeks.~Maintenance therapy with nivolumab 480 mg; 21 infusions, every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Induction therapy with ipilimumab 1 mg/kg; 4 infusions, every 3 weeks.
Study: NCT05606081

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Logistic regression risk model
Description: Logistic regression model to assign risk score, plus time overdue and PROMPT risk category
Study: NCT05467475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1819479
Description: BI 1819479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1819479
Description: BI 1819479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole
Study: NCT05445401

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-rehabilitation
Description: Triple pre-rehabilitation interventions of exercise, nutrition and psychology

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard medical care
Description: Traditional care
Study: NCT04609813

Intervention type: DIAGNOSTIC_TEST
Intervention: Sponge cytological test
Description: Esophageal cell specimen were collected with Esoheal 1.0 sponge collection device. A prediction model will be built based on digital cytopathological features of participants.
Study: NCT05005455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab with new manufacturing process.
Description: 3mg/kg,I.V.,single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab with old manufacturing process.
Description: 3mg/kg,I.V.,single dose
Study: NCT05164055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avalglucosidase alfa (GZ402666)
Description: Pharmaceutical form: Sterile lyophilized powder Route of administration: intravenous (IV) infusion
Study: NCT06118151

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Hemagglutinin mRNA vaccine
Description: Pharmaceutical form:Solution for injection-Route of administration:IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Hemagglutinin mRNA vaccine
Description: Pharmaceutical form:Solution for injection-Route of administration:IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Hemagglutinin mRNA vaccine
Description: Pharmaceutical form:Solution for injection-Route of administration:IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Hemagglutinin mRNA vaccine
Description: Pharmaceutical form:Solution for injection-Route of administration:IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Hemagglutinin mRNA vaccine
Description: Pharmaceutical form:Solution for injection-Route of administration:IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Hemagglutinin mRNA vaccine
Description: Pharmaceutical form:Solution for injection-Route of administration:IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Recombinant Influenza Vaccine
Description: Pharmaceutical form:Solution for injection-Route of administration:IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Recombinant Influenza Vaccine
Description: Pharmaceutical form:Solution for injection-Route of administration:IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Recombinant Influenza Vaccine
Description: Pharmaceutical form:Solution for injection-Route of administration:IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Recombinant Influenza Vaccine
Description: Pharmaceutical form:Solution for injection-Route of administration:IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Recombinant Influenza Vaccine
Description: Pharmaceutical form:Solution for injection-Route of administration:IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Recombinant Influenza Vaccine
Description: Pharmaceutical form:Solution for injection-Route of administration:IM injection
Study: NCT06125912

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dime Beauty TBT Cream
Description: Test product contains: Water, Ammonium Acryloyldimethyltaurate/VP Copolymer, Behenyl Alcohol, Dimethicone, Caprylic/Capric Tiglyceride, Cetearyl Alcohol, Dimethicone Crosspolymer, Glycerin, Glyceryl Stearate, Pentylene Glycol, 1,2-Hexanediol, Isododecane, Linoleic Acid, Caprylic/Capric/Succinic Triglyceride, Octadecene, Olea Europaea (Olive) Oil Unsaponifiables, Orobanche Rapum Extract, Phospholipids, Phytosterols, Polyglyceryl-6 Behenate, Polyglyceryl-6 Stearate, Propanediol, Pyrus Malus (Apple) Fruit Extract, Caprylic/Capric/Myristic/Stearic Triglyceride, Stearyl Dimethicone, Hydroxyacetophenone, Bakuchiol, Cetyl Ricinoleate, Tetrasodium Glutamate Diacetate, Tocopherol, Xanthan Gum.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive Control
Description: Water, Glycerin, Caprylic/Capric Triglyceride, Helianthus Annuus (Sunflower) Seed Oil, Pentylene Glycol, 1,2-Hexanediol, Cetearyl, Alcohol, Glyceryl Stearate, PEG-100 Stearate, Dimethicone, Hydroxyacetophenone, Sodium Ascorbate, Tocopherol, Carbomer, Xanthan Gum, Retinol, PEG-40 Hydrogenated Castor Oil.
Study: NCT06037642

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABC 0-2 years
Description: Four 1 hour meetings and homework

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: waiting list
Description: Will be put on hold for four weeks
Study: NCT05608382

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sterile Phosphate Buffer Saline
Description: control group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SGW13
Description: active comparator
Study: NCT05452330

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Connective tissue massage
Description: Connective tissue massage will be applied with short and long pulling strokes to create a reflex effect for 2 days a week, a total of 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical massage
Description: Classical massage will be applied with the techniques of stroking, kneading, and friction for 2 days a week, a total of 8 weeks.
Study: NCT04660526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid cardiac arrest recognition that triggers immediate priority EMS/first responder dispatch by 911 operators
Description: EMS first responders will recognize cardiac arrest and respond immediately, increasing time to dispatch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systematic bystander resuscitation instruction by 911 operators
Description: 911 operators will be able to describe how to administer CPR over the phone.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive community training of lay people in CPR and AED use.
Description: Training of lay people regarding CPR and AED use.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimized first responder performance including earlier use of AEDs.
Description: First responders will recognize where AEDs are located and use them appropriately
Study: NCT04703036

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glycine
Description: Glycine is an amino-acid (protein)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: This is a donor of the amino-acid cysteine (protein)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alanine
Description: Alanine is an amino-acid (protein)